Targeting glutamatergic synapses in Parkinson's disease

Curr Opin Pharmacol. 2015 Feb:20:24-8. doi: 10.1016/j.coph.2014.10.011. Epub 2014 Nov 17.

Abstract

Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons of the substantia nigra and dramatic motor and cognitive impairments. The current knowledge indicates that the strength of glutamatergic signals from the cortex to the striatum is regulated during the progression of the disease. The efficacy of ionotropic glutamate receptors to modulate synaptic transmission in the striatum indicates that modulation of the activity of these receptors may represent a key target to rescue the altered neurotransmission in PD. Preclinical and clinical studies suggest that agents targeting ionotropic glutamate receptors may ameliorate the motor symptoms of PD as well as to reduce the onset of levodopa-induced dyskinetic motor behaviour.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiparkinson Agents / adverse effects
  • Antiparkinson Agents / pharmacology*
  • Disease Progression
  • Dopaminergic Neurons / pathology
  • Dyskinesia, Drug-Induced / prevention & control
  • Humans
  • Levodopa / adverse effects
  • Levodopa / pharmacology
  • Molecular Targeted Therapy
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Receptors, Ionotropic Glutamate / drug effects*
  • Receptors, Ionotropic Glutamate / metabolism
  • Synaptic Transmission / physiology

Substances

  • Antiparkinson Agents
  • Receptors, Ionotropic Glutamate
  • Levodopa